Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 10, 2004, Pages 1642-1648

  Taguchi, Masato ^a   Nozawa, Takashi ^b   Mizumaki, Kouichi ^b   Inoue, Hiroshi ^b   Tahara, Katsutoshi ^a   Takesono, Chihiro ^a   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aging; Japanese patient; Metoprolol; Nonlinear mixed effects model (NONMEM); Pharmacokinetics; Whole blood concentration

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; METOPROLOL TARTRATE; CYP2C19 PROTEIN, HUMAN; METOPROLOL; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ANALYTIC METHOD; ARTICLE; ASIAN; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GENDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HUMAN; MALE; STEADY STATE; AGE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; GENETICS; HYPERTENSION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NONLINEAR SYSTEM; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; METABOLIC CLEARANCE RATE; METOPROLOL; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NONLINEAR DYNAMICS; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 19644374120     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.1642     Document Type: Article

References (35)

1. Bradford L. D., Pharmacogenomics, 3, 229-243 (2002).
2. Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjöqvist F., Clin. Pharmacol. Ther., 51, 388-397 (1992).
3. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A., Clin. Pharmacol. Ther., 38, 402-408 (1985).
4. Huang J. D., Chuang S. K., Cheng C. L., Lai M. L., Clin. Pharmacol. Ther., 65, 402-407 (1999).
5. Johansson I., Lundqvist E., Bertilsson L., Dahl M. L., Sjöqvist F., Ingerman S. M., Proc. Natl. Acad. Sci. U.S.A., 90, 11825-11829 (1993).
6. Yokota H., Tamura S., Furuya H., Kimura S., Watanabe M., Kanazawa I., Kondo I., Gonzalez F. J., Pharmacogenetics, 3, 256-263 (1993).
7. Johansson I., Oscarson M., Yue Q. Y., Bertilsson L., Sjöqvist F., Ingerman S. M., Mol. Pharmacol., 46, 452-459 (1994).
8. Tateishi T., Chida M., Ariyoshi N., Mizorogi Y., Kamataki T., Kobayashi S., Clin. Pharmacol. Ther., 65, 570-575 (1999).
9. Nishida Y., Fukuda T., Yamamoto I., Azuma J., Pharmacogenetics, 10, 567-570 (2000).
10. Roh H. K., Chung J. Y., Oh D. Y., Park C. S., Svensson J. O., Dahl M. L., Bertilsson L., Br. J. Clin. Pharmacol., 52, 265-271 (2001).
11. Taguchi M., Nozawa T., Kameyama T., Inoue H., Takesono C., Mizukami A., Hashimoto Y., Eur. J. Clin. Pharmacol., 59, 385-388 (2003).
12. Regårdh C. G., Borg K. O., Johansson R., Johansson G., Palmer L., J. Pharmacokinet. Biopharm., 2, 347-364 (1974).
13. Regårdh C. G., Johnsson G., Clin. Pharmacokinet., 5, 557-569 (1980).
14. Wilkinson G. R., Shand D. G., Clin. Pharmacol. Ther., 18, 377-390 (1975).
15. Regårdh C. G., Landahl S., Larsson M., Lundborg P., Steen B., Hoffmann K. J., Lagerström P. O., Eur. J. Clin. Pharmacol., 24, 221-226 (1983).
16. Kendall M. J., Brown D., Yates R. A., Br. J. Clin. Pharmacol., 4, 497-499 (1977).
17. Rendic S., Drug. Metab. Rev., 34, 83-448 (2002).
18. Luzier A. B., Killian A., Wilton J. H., Wilson M. F., Forrest A., Kazierad D. J., Clin. Pharmacol. Ther., 66, 594-601 (1999).
19. Johnsson G., Regårdh C. G., Sölvell L., Acta Pharmacol. Toxicol., 36 (Suppl. V), 31-44 (1975).
20. Lamba J. K., Dhiman R. K., Kohli K. K., Clin. Pharmacol. Ther., 68, 328-335 (2000).
21. Hamelin B. A., Bouayad A., Méthot J., Jobin J., Desgagnés P., Poirier P., Allaire J., Dumesnil J., Turgeon J., Clin. Pharmacol. Ther., 67, 466-477 (2000).
22. Sheiner L. B., Beal S. L., J. Pharmacokin. Biopharm., 11, 303-319 (1983).
23. Beal S. L., Boeckmann A. J., Sheiner L. B., "NONMEM Users Guides: NONMEM Project Group," University of California, San Francisco, 1992.
24. Wilkinson G. R., Pharmacol. Rev., 39, 1-47 (1987).
25. Fukuda T., Nishida Y., Imaoka S., Hiroi T., Naohara M., Funae Y., Azuma J., Arch. Biochem. Biophys., 380, 303-308 (2000).
26. Castleden C. M., Kaye C. M., Parsons R. L., Br. J. Clin. Pharmacol., 2, 303-306 (1975).
27. Castleden C. M., George C. F., Br. J. Clin. Pharmacol., 7, 49-54 (1979).
28. Ward S. A., Walle T., Walle U. K., Wilkinson G. R., Branch R. A., Clin. Pharmacol. Ther., 45, 72-79 (1989).
29. Borg K. O., Carlsson E., Hoffmann K. J., Jönsson T. E., Thorin H., Wallin B., Acta Pharmacol. Toxicol., 36, 125-135 (1975).
30. Zoli M., Magalotti D., Bianchi G., Gueli C., Orlandini C., Grimaldi M., Marchesini G., Age and Ageing, 28, 29-33 (1999).
31. Kirchheiner J., Müller G., Meineke I., Wernecke K. D., Roots I., Brockmöller J., J. Clin. Psychopharmacol., 23, 459-466 (2003).
32. MERIT-HF study group, Lancet, 353, 2001-2007 (1999).
33. Poole-Wilson P. A., Swedberg K., Cleland J. G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W. J., Torp-Pedersen C., Scherhag A., Skene A., Carvedilol Or Metoprolol European Trial Investigators, Lancet, 362, 7-13 (2003).
34. Bergstrand R. H., Vedin J. A., Wilhelmsson C. E., Berglung G., Eur. J. Clin. Pharmacol., 10, 375-379 (1976).
35. Tuomilehto J., Pohjola M., Ann. Clin. Res., 10, 24-29 (1978).